Monte Rosa Therapeutics
GLUE
71 hedge funds and large institutions have $227M invested in Monte Rosa Therapeutics in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 13 closing their positions.
135% more call options, than puts
Call options by funds: $2.9M | Put options by funds: $1.24M
13% more capital invested
Capital invested by funds: $201M → $227M (+$25.7M)
0% more funds holding
Funds holding: 71 → 71 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
4.9% less ownership
Funds ownership: 85.14% → 80.24% (-4.9%)
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$601K |
| 3 |
Morgan Stanley
New York
|
+$498K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$356K |
| 5 |
Jane Street
New York
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.19M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$3.89M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.83M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.53M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$624K |
GLUE Hedge Fund Activity: Q4 2023 in Review
71 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2023, worth a combined $227M — up 13% from $201M a quarter earlier.
Fund positioning in GLUE was balanced in Q4 2023: 13 funds opened new positions, 13 closed out, 15 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $4.2M. The largest seller was BlackRock, cutting an estimated $5.19M.
- 71 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $227M of Monte Rosa Therapeutics stock for Q4 2023, up 13% quarter-over-quarter.
- 13 funds opened new Monte Rosa Therapeutics positions in Q4 2023 and 13 closed out, a net change of 0 holders.
- The largest Monte Rosa Therapeutics buyer in Q4 2023 was T. Rowe Price Associates, an estimated $4.2M added.
- The largest Monte Rosa Therapeutics seller in Q4 2023 was BlackRock, an estimated $5.19M sold.
Based on aggregated 13F filings for Q4 2023.